USA - NASDAQ:TSHA - US8776191061 - Common Stock
We assign a fundamental rating of 2 out of 10 to TSHA. TSHA was compared to 534 industry peers in the Biotechnology industry. While TSHA seems to be doing ok healthwise, there are quite some concerns on its profitability. TSHA does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.82% | ||
| ROE | -37.28% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.9 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.48 | ||
| Quick Ratio | 12.48 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:TSHA (10/28/2025, 11:44:16 AM)
4.915
+0.04 (+0.72%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 165.57 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.39 | ||
| P/tB | 5.39 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.82% | ||
| ROE | -37.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 35.66% | ||
| Cap/Sales | 5.1% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 12.48 | ||
| Quick Ratio | 12.48 | ||
| Altman-Z | 6.9 |
ChartMill assigns a fundamental rating of 2 / 10 to TSHA.
ChartMill assigns a valuation rating of 0 / 10 to TAYSHA GENE THERAPIES INC (TSHA). This can be considered as Overvalued.
TAYSHA GENE THERAPIES INC (TSHA) has a profitability rating of 1 / 10.
The financial health rating of TAYSHA GENE THERAPIES INC (TSHA) is 5 / 10.